Concord Drugs Ltd Financial Ratios
CONCORDDRUGSLTD · Healthcare · Current price
P/E ratio
89.8x
P/B ratio
1.9x
ROE
2.5%
ROCE
4.7%
Debt / Equity
0.24
Dividend yield
0.0%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 89.8x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 1.9x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 2.5% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 4.7% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.24 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with Concord Drugs Ltd's latest numbers.
Concord Drugs Ltd profitability
Concord Drugs Ltd generates a return on equity of 2.5% and a return on capital employed of 4.7%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.24 and a P/E of 89.8x, Concord Drugs Ltd is conservatively financed. Our overall business-quality score for the company is 2.8 / 10.
Understand the ratios
More on Concord Drugs Ltd
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.